Novartis Receives EU Approval for Cosentyx's (secukinumab) Label Update in Patients with Psoriatic Arthritis (PsA)
Shots:
- The label update includes dosing flexibility of Cosentyx up to 300 mg based on clinical response & SC structural data of 24 wks.- showing inhibition in progression of joint damage in PsA
- Cosentyx label update is based on safety and efficacy of 300mg in follow-up titration & results from P-III FUTURE 5 study (N=996) @24 wks. showing results of no radiographic disease progression in 90% of patients
- Cosentyx is novel inhibitor for IL-17A in PsA & AS- prescribed to 160-000 patients WW. The updated label is applicable in EU including all EEA countries
to read full press release/ article
Ref: Novartis | Image: Novartis
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com